Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD relaxes restrictions on flunixin
"Flunixin is a unique medicine in managing pain and sepsis in horses with colic."
Short-term access restored for non-food producing horses 

The Veterinary Medicines Directorate (VMD) has temporarily relaxed the restrictions that were recently imposed on the equine painkiller flunixin.

VMD has allowed the release of stock from manufacturers, which will restore short-term access to this medicine, for use in non-food producing horses.

Medicines for food-producing animals that contain the excipient diethanolamine (DEA) were recently suspended by the VMD. The decision was made following a scientific opinion from the European Medicines Agency, which highlighted concerns that there may be a risk to humans.

Among other products, flunixin 50mg/ml solution for injection was suspended, prompting concern among vets about the potential future lack of this drug for intravenous use in non-food producing horses. VMD said it is investigating potential ways to maintain the availability of injectable flunixin for use in these horses.

Commenting on the relaxation of the restrictions, BEVA president Jon Pycock said: “It remains a concern to BEVA that this mechanism was not put in place before the suspension of flunixin was imposed.

“Contrary to assertions by the VMD, wholesalers were unable to meet the demands of the veterinary profession and clinical use of this medicine was disrupted within 24 hours of the VMD’s initial announcement.

“We are surprised by the Regulator’s lack of awareness of availability in the supply chain and question why there was no consultation with the veterinary sector before the suspension was enacted. The VMD has been aware of this issue since March 2018 and it appears that no contingency was put in place to consider the animal welfare impact of this decision until it was too late.”

Tim Mair, BEVA junior vice president and specialist in equine surgery added: “Flunixin is a unique medicine in managing pain and sepsis in horses with colic. The VMD appeared to believe that this medicine could be substituted for other veterinary medicines and this is simply not the case.

“The release of stock from manufacturers is a short-term solution and, looking forward, we would like assurances that the VMD will fast track applications for the modification of product licenses to ensure that equine vets have continued access to these products.”

Stocks of flunixin held by manufacturers will be distributed with a caution letter, which explains the restricted use of the product.

BEVA is reminding all equine vets to check the horse’s food chain status when using the product - either by examining the paper passport or the recently launched chip checker on the Central Equine Database website.

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
NSA webinar explores sheep tailing and castration

The National Sheep Association (NSA) is to host a free webinar on the castration and tail docking of lambs.

The webinar, 'Understanding the tailing and castration consultation: A guide for sheep farmers', will be hosted online on Monday, 2 March 2026 at 7.30pm.

It comes during a government consultation into the methods used for these procedures. Farmers are encouraged to engage before the consultation period closes on Monday, 9 March 2026.

The webinar offers clear and actionable guidance to support farmers to contribute meaningfully to the consultation and prepare for potential changes.

On the panel will be former SVS president Kate Hovers, farmer and vet Ann Van Eetvelt and SRUC professor in Animal Health and Veterinary Sciences Cathy Dwyer. Each panel member will utilise their own specialism and expertise to evaluate risks and outcomes to sheep farming.

Find out more about the webinar on the NSA website.